Key words: protein kinase C/annexin/antiestrogen/membrane-protein interaction ABSTRACT. The mechanism by which nonsteroidal antiestrogen inhibits Ca2+-and phospholipid-dependent protein kinase (PKC) activity was investigated. Antiestrogenic agents, clomiphene and tamoxifen, inhibited the PKC-dependent phosphorylation of histone and r-annexin I in a dose-dependent manner. Ki values for the agents were different for two substrate proteins. The inhibitory action of the agents depended on the membranesubstrate protein interaction. Phosphorylation of cytoplasmic proteins obtained from rat uterus and mammary gland, including annexin I, by endogenous PKC was also inhibited by low concentrations of these agents. These results suggest that the inhibitory action of nonsteroidal antiestrogens occurs through their inhibitory effect on the membrane-substrate protein interaction.
phospholipid-dependent protein kinase (PKC) might be involved in the inhibitory mechanism of clomiphene and tamoxifen (7-1 1) . The agents inhibited the phosphorylation of histone by PKCobtained from human ovary (7, 9) , placenta (7) and rat brain (8) (9) (10) . Tamoxifen inhibited the PKC-dependent phosphorylation of synthetic peptide by all subspecies of PKCpurified from the breast cancer cell line (ll).
Phosphorylation of cytoplasmic proteins of rat ovary by endogeneous PKCwas also inhibited by tamoxifen (9) . However, the precise mechanismfor the inhibitory action of these antiestro-1 To whomcorrespondence should be addressed.
Abbreviations used: CBB, Coomassie brilliant blue; DPPC, dipalmitoylphosphatidylcholine; PS, phosphatidylserine; PKC, Ca2+-phospholipid-dependent protein kinase; PMSF, phenylmethylsulfonyl fluoride; r-annexin I, recombinant annexin I; TPA, 12-0-tetradecanoyl phorbol-13-acetate.
gens were not elucidated. PKC is a Ca2+-dependent membrane-binding protein (12) . Binding to the cell membrane and the activation of PKCrequire acidic phospholipids, such as phosphatidylserine (PS). Activation of PKC closely correlates with the mobilization of intracellular Ca2+ and the activation of phospholipases. PKChas been assumed to be a key regulatory enzyme in many cellular events (12). Thus, it is plausible to consider that the biological action of nonsteroidal antiestrogen might depend, at least in part, on their inhibitory effect on PKC.
Another type of Ca2+-dependent membrane-binding protein, namedannexin, has been recently identified; manynamesare used for each member of this protein family, such as lipocortin or calpactin, and the term "annexin" with the numbering system of lipocortin has been suggested (13). Like PKC, these proteins also associate with PS containing phospholipid membranes depending on Ca2+ concentrations (14-17). Several proteins in this family are phosphorylated by PKC, p60src, insulin-receptor kinase and EGF-receptor kinase by a mechanismwhich requires them to bind to membranes (14, (18) (19) (20) (21) (22) (23) . Thus, these proteins might be useful for studying the role of membrane-substrate protein interaction in the mechanismof activation of protein kinase. The present work discusses the mechanism by which PKC activity is inhibited by nonsteroidal antiestrogens in view of their effect on the interaction of PKCsubstrates with membranes. Nacalai Tesque (Kyoto, Japan).
Preparation ofphospholipid vesicles. Phospholipids dissolved in chloroform and methanol (3/1 , vol/vol) were evaporated in vacuo at 50°C. The residue was dispersed in 20 mM Tris-HCl (pH 7.5) containing 100 mMNaCl. The suspension was sonicated by a Branson Sonifier (Cell Disrupter 185) at 50°C for 45 min under the flow ofN2 gas followed by centrifugation (10,000 x g, 5 min) (24) to eliminate titanium. The supernatant was used as phospholipid membranes. Preparation of PKC from rat brain. PKC was partially purified from the brain soluble fractions of Wistar male rats weighing 250 to 300 g. Briefly, the brains were homogenized in 20mMTris-HCl (pH 7.5), 0.25 M sucrose, 10mM EDTA, 5 mMEGTA, 10 mM/3-mercaptoethanol and 0.1% Triton X-100 followed by centrifugation (100,000 x g, 1 h). The supernatant applied to a DE-52 column equilibrated with 20 mM Tris-HCl (pH7.5), 0.5mM EGTA, 0.5mM EDTA and 10 mM/3-mercaptoethanol (buffer A). The column was washed with buffer A containing 30 mMNaCl. PKCwas eluted from the column with buffer A containing 100 mMNaCl. The DE-52 fraction was applied to a TSKG-3000SWcolumn equilibrated with 20mM Tris-HCl (pH 7.5) containing 0.5 mM EDTA, 0.5 mMEGTA, 10 mM/3-mercaptoethanol and 100 mMNaCl. The active fractions were collected and were used as partially purified PKC. Preparation of uterus and mammarygland cytoplasmic proteins. Uterus and mammary gland were obtained from Wistar rats. After sacrifice by exsanguination, the abdominal skin of a pregnant rat at the 7 th day after mating was rapidly removed and the mammarygland was scraped off. The uterus at oestrus was used. The organs were homogenized with polygon homogenizer at 4°C in 20 mMTris-HCl buffer (pH 7.5) containing0.15 M KC1, 1 mMPMSF, 0.01% leupeptin, 5 mM EDTAand 2 mMEGTA.The homogenates were centrifuged at 100,000xg for 1 h. These supernatants were applied to a Sephadex G-25 column equilibrated with 20 mMTris-HCl (pH 7.5) and 0.15 MKC1. The macromolecular fractions were used as the cytoplasmic proteins. Preparation ofannexin I. Annexin I is identical to lipocortin I, p35, calpactin II, chromobindin 9 or GIF. Recombinant annexin I (r-annexin 1) expressed in Saccharomyces cerevisiae was purified as described previously (23). Briefly, the yeast cells were disrupted with bead beader in the presence of EGTAand protenase inhibitors followed by centrifugation at 5000xg for 30 min. Ca2+ was added to the supernatant and centrifuged at 100,000xg for 1 h. The pellet was corrected, suspended in the buffer containing EGTAand protenase inhibitors and centrifuged at 100,000 x g for 1 h. The supernatant was corrected and salted out with (NH4)2SO4 (saturation level of 100%). The precipitate was dissolved in 25 mMtriethanolamine-iminodiacetic acid (pH 8.3), dialyzed against the same buffer, and applied to a MonoP column. r-Annexin I was eluted with 10% polybuffer-iminodiacetic acid (pH 5.0) followed by gel filtration (TSK G-3000SW). r-Annexin I was purified to homogeneity by these procedures. and histone) or by the density of the film of autoradiography at 600 nm (r-annexin I) following SDS-PAGE (27). Binding assay of PKCsubstrate proteins to phospholipid vesicles. The interaction of histone or r-annexin I with phospholipid vesicles was analyzed by the flotation method (24, 28). Briefly, the PKC substrate proteins (100 /ug/m\) were incubated with small unilamellar vesicles (200juM, DPPC or DPPC/PS, 4/1, and 100nM TPA) at 30°C for 5min in 20 mMTris-HCl (pH 7.5), 10mM magnesium acetate, 50mM NaCl and 0.3 mMCa2+ or 1 mMEGTA, and then mixed with an equal volume of 1.12 density Ficoll 400 solution dissolved in 20 mMTris-HCl buffer (pH 7.5) containing 50 mM NaCl, 10 mMmagnesium acetate and 0.3 mMCa2+ or 1 mMEGTA. The mixture was layered within a discontinuous Ficoll density gradient of 1.05 and 1.01 dissolved in 20mM Tris-HCl (pH 7.5) and 0.3 mMCa2+, and centrifuged at 100,000xg at 30°C for 1 h. The liposomes which floated upward through this gradient were collected, and analyzed by silver staining following to SDS-PAGE.
Immunoblot analysis. The presence of annexin I in the cytosol was detected by immunoblotanalysis using a commercially available kit (ELC Western blotting detection system, AmershamInternational pic), which detects immunoreactive materials as chemiluminescence. The primary antibody used was anti-r-annexin I-rabbit antibody prepared in our laboratory.
RESULTS
Effect of antiestrogens on protein phosphorylation by PKC. Nonsteroidal antiestrogens, such as clomiphene and tamoxifen, inhibited PKCactivity. The inhibitory activity of antiestrogens differs depending on the concentration of the phospholipid used. It has been suggested that the agents inhibit PKCby way of competing with PS (8, 9) . In the presence of 100nM TPA, the half-maximum concentration of phospholipid (DPPC/ PS, 4/1) for the PKC-dependent phosphorylation of histone was 17.5 juM (3.5 juM for PS) (data not shown).
Thus, we determined the inhibitory action of clomiphene and tamoxifen on the PKC-dependent phosphorylation of histone and annexin I in the presence of 17.5 juM phospholipid. The Ki values of tamoxifen and clomiphene for the phosphorylation of histone were 40 M and 50juM, respectively (Fig. 1A) . However, the phosphorylation of protamine sulfate, which does not require Ca2+, PS or TPA, was not inhibited by these agents up to 200juM, as reported previously (8, 10) .
Based on such observations, O'Brian et al. speculated that nonsteroidal antiestrogens might inhibit PKCactivity by interacting with the regulatory domain of PKC rather than with its catalytic domain (8) . Annexin I is an intracellular protein that serves as a substrate for PKC.This protein associates with PS containing liposomes in a Ca2+-dependent fashion, and is phosphorylated by PKC (14, 23). Phosphorylation of rannexin I was inhibited by these agents in a dose-dependent manner. The Ki value of r-annexin I (1.5 juM) was much lower than that of histone ( Association of r-annexin I with phospholipid membranes required Ca2+ and PS (Fig. 3B) ; weak association of r-annexin I with DPPCmembranewas observed in the presence of 10~4 MCa2+ (data not shown).
Membrane-r-annexin I association was inhibited strongly by tamoxifen; the dose dependency of the inhibition of the membraneassociation also closely correlated with the inhibition of phosphorylation (Fig. 3A) .
These results suggested that the inhibitory activity of tamoxifen on the interaction of histone and r-annexin I with phospholipid membranes might be responsible for was increased by Ca2+, 200 juM phospholipid and TPA.
Phosphorylation of these proteins was strongly inhibited by the antiestrogens. However, 23 kDa protein was not inhibited by these agents up to 150juM. This phosphorylation appears to depend on PKC because it requires Ca2+, PS and TPA.
These phosphoproteins were not characterized in these tissues. Since annexin I is widely distributed in many tissues, distribution of annexin I was expected in these phosphoproteins. Thus, we tested whether annexin I is presented in rat mammarygland and uterus by immunoblot analysis.
The anti-r-annexin I antibody specifically reacted with annexin I from several mammals but not to other proteins of the annexin family (data not shown). As shownin Fig. 6 , annexin I was detected in cytoplasmic fractions from both the rat mammary gland and uterus. The apparent molecular weight dicate that PKC-dependent phosphorylation of 37 kDa protein might include annexin I, and that the phosphorylation was inhibited by the antiestrogens (Figs. 4 and   5 ).
DISCUSSION
Although it has been generally accepted that the pharmacological action of tamoxifen and clomipheneoccurs by way of competition with estrogen for its receptor (1) (2) (3) (4) , a fairly large dose of estrogen overcame the effect of nonsteroidal antiestrogens only partially in several physiological events (4) (5) (6) . Furthermore, the binding sites for nonsteroidal antiestrogens, distinct from the estrogen receptor, are present in many tissues, including the target organs of estrogen (31, 32).
Since the inhibitory action of tamoxifen and clomiphene on PKCactivity was demonstrated, the enzyme is postulated to be one of the targets of these agents (7-1 1). These antiestrogens inhibit PKCactivity by way of their competition with PS (8) . Furthermore, phosphorylation of protamine sulfate, which does not require Ca2+, PS or TPA, was not inhibited by these agents. Hence, the following mechanism for the inhibition by these agents has been proposed (10): these agents interact with PS but not with the catalytic site of PKC,thereby inhibiting the enzyme action. Although nonsteroidal antiestrogens have some affinity for the regulatory domain of PKC(33), there is no indication that the agents compete with PS for the same site of this domain (26). The mechanismby which the interaction of the agents with PS inhibits the PKCactivity is not understood. The present work confirmed that the antiestrogens inhibited the phosphorylation of histone by PKC, but did not inhibit that of protamine sulfate. The effect of these agents to inhibit the phosphorylation was 5-30 times higher with r-annexin I than with histone. These results strongly suggest that the agents inhibit the phosphorylation of r-annexin I by some mechanism other than direct inhibition of PKCactivity. Annexin I is a Ca2+-and PS-dependent membrane binding protein. The PKC-dependent phosphorylation of annexin I requires Ca2+-induced association of this protein to the membrane (14, 23). Binding is also required for the phosphorylation of histone to PS-containing membranes (24, 34 Amongvarious annexins, annexin I, IV and VI are phosphorylated by PKC in vitro (14, 40, 41) . The present work demonstrates the presence of annexin I (37 kDa) in the cytosol from both the rat mammarygland and uterus. The phosphoprotein with molecular weight similar to that of annexin I was also observed in the presence of Ca2+, PS and TPA. Phosphorylation of the protein was inhibited by the antiestrogens at 30-75 juM, and the dose dependency corresponded to that of annexin I (Fig. 3) . These results suggested that annexins in mammarygland and uterus cytosol might be phosphorylated by PKCand inhibited by an antiestrogen-inhibitable mechanismin which the interaction of annexins with membranous PS play critical role. Since the phosphorylation of 22 kDa protein in the mammarygland, 23 kDa protein in the uterus and 86-80 kDa proteins in both tissues were not inhibited by high concentration of the agents, interaction of these proteins with membranes may not be inhibited by these agents. Different Ki values of nonsteroidal antiestrogens for the inhibition of PKCwere reported by various investigators (7-ll) . The reason for such differences may depend on the phospholipid concentrations used. In this study, we confirmed that increase of the phospholipid concentration increased Ki values for the inhibition of phosphorylation of histone and annexin I (Fig. 1, Fig. 2 and Fig. 3 ). The lowest Ki value of tamoxifen for PKC activity is 1-3 juM (10) . Since the activity of these agents to inhibit annexin I phosphorylation was 5-30 times stronger than that on histone phosphorylation, Ki values of these agents for annexin I phosphorylation may be of nanomolar ranges under the same experimental conditions. Clomiphene, a therapeutic agent for infertility, releases gonadotropin from the pituitary gland. Since the effective plasma level of the agent is in the nanomolar range, the mechanism of the agent might involve the competition with estrogen. Studies using primary culture cells from the pituitary gland revealed that LHreleasing hormone enhanced phosphatidylinositol turnover, and TPA-induced LH release from pituitary cells (44, 45) . If clomiphene inhibited the PKC-dependent phosphorylation of some cytoplasmic proteins of the pituitary gland at nanomolar concentrations, the mechanism for the gonadotropin-releasing effect of clomiphene other than competition with estrogen should be considered. Further investigation is required to elucidate the molecular mechanismby which these nonsteroidal agents exert their pharmacological action. J., Miquel, J., and Nishizuka, Y. (1989 
